Eric L. Reyner

Development of a new permeability assay using low‐efflux MDCKII cells

Li Di, Carrie Whitney‐Pickett, John P. Umland et al. · Journal of Pharmaceutical Sciences · 2011 · 311 citations

Membrane Transport, Membrane Biology, Biomedical Engineering +6

Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor:  4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-<i>d</i>]pyrimidine-6-acrylamides Bearing Additional Solubilizing Functions

Jeff B. Smaill, Gordon W. Rewcastle, Joseph A. Loo et al. · Journal of Medicinal Chemistry · 2000 · 263 citations · Full text

Combinatorial Chemistry, Organic Chemistry, Pharmacotherapy +21

Comparison of Intestinal Permeabilities Determined in Multiple in Vitro and inSitu Models: Relationship to Absorption in Humans

Barbra H. Stewart, O. Helen Chan, Rosalind H. Lu et al. · Pharmaceutical Research · 1995 · 186 citations

Atorvastatin Coadministration May Increase Digoxin Concentrations by Inhibition of Intestinal P-Glycoprotein-Mediated Secretion

Rebecca A. Boyd, R. H. Stern, Barbra H. Stewart et al. · The Journal of Clinical Pharmacology · 2000 · 172 citations

Inflammation, Molecular Pharmacology, Intestinal P-glycoprotein-mediated Secretion +14

Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria

Joe Bentz, Michael O′Connor, Dallas Bednarczyk et al. · Drug Metabolism and Disposition · 2013 · 147 citations · Full text